Secondary Hyperparathyroidism
Treatment Market: Regional Insights
On the basis of region, the
global Secondary
Hyperparathyroidism Treatment Market by Coherent Market Insights is
segmented into North America, Latin America, Europe, Asia Pacific, Middle East,
and Africa. North America holds a dominant position in the global secondary
hyperparathyroidism treatment market, owing to increasing research and
development of novel therapies and potential drugs for secondary
hyperparathyroidism as well as high prevalence of chronic kidney disease.
According to the Centers of Disease Control & Prevention (CDC), in 2014,
118,000 people in the U.S. started treatment for ESRD, and 662,000 were living
on chronic dialysis. Furthermore, Europe is expected to be the second-largest
contributor in the secondary hyperparathyroidism treatment market, in terms of
revenue and is expected to gain significant traction in the near future. This
is owing to launch of new drugs and therapies, to combat secondary
hyperparathyroidism as well as presence of significant population suffering
from the disease in this region. For instance, in December 2016, Amgen’s drug
etecalcetide (Parsabiv), received marketing approval in Europe by the European Commission
for treatment of secondary hyperparathyroidism in adult patients with chronic
kidney diseases. Furthermore, Asia Pacific is expected to be the fastest
growing region, owing to regional companies conducting clinical trials for
launch of new drugs. For instance, Kyowa Hakko Kirin China Pharmaceutical Co.,
Ltd is under Phase 4 clinical trial to determine the safety and efficacy of its
new lead compound Cinacalet for treatment of patients suffering with mild to
moderate SHPT and expected to be launched in the market by April 2019.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1570
Secondary hyperparathyroidism
(SHPT) refers to one of the serious, common, and progressive complication
associated with Chronic Kidney Disease (CKD) that is mainly characterized by
high levels of parathyroid hormone, mineral metabolism abnormalities, and parathyroid
gland hyperplasia. Failing kidneys are unable to convert Vitamin A to its
active form as they do not adequately excrete phosphate resulting into
formation of insoluble calcium phosphate by the body thus, leading to secondary
hyperparathyroidism. The common signs and symptoms of the disease includes bone
and joint pain as well as limb deformities. The disturbances caused in the
secondary hyperparathyroidism patients may lead to poor quality of life and
short life expectancy. Treatment for SHPT involves surgical operation or
consumption of prescribed drugs that helps to maintain the level of parathyroid
hormone, calcium, and phosphorous within the accepted targeted areas. According
to the U.S. Food & Drug Administration (FDA) 2012, Secondary hyperparathyroidism
is a serious chronic condition that affects a high percentage of patients
receiving kidney dialysis. In case of prognosis, if the SHPT is left untreated,
the disease progresses to tertiary hyperparathyroidism and is then associated
with hypercalcemia. According to the National Institute of Diabetes &
Digestive & Kidney Diseases, the two prime reasons resulting in chronic
kidney disease are diabetes and high blood pressure. Patients suffering from
CKD, due to one of the reasons, if remain undetected can progress to
irreversible kidney failure.
Secondary Hyperparathyroidism Treatment
Market: Market Dynamics
Rising incidence of chronic
kidney diseases is one of the major factors responsible for growth of the
global secondary hyperparathyroidism treatment market. According to Centers of
Disease Control & Prevention (CDC) 2017, 30 million people or 15% of the
U.S. adults are estimated to have chronic kidney disease, out of which 48%
suffer severely with reduced kidney function, however, are not aware of having
a CKD.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/secondary-hyperparathyroidism-treatment-market-1570
Moreover, according to the
National Kidney Foundation 2016, 10% of the population across the world are
affected with chronic kidney diseases. Additionally, extensive research in the
field of nephrology to come up with new drugs and therapies for treatment of
secondary hyperparathyroidism is responsible for fueling growth of the market.
For instance, Sanofi SA’s Hectorol capsules is undergoing Phase 3 clinical
trials to evaluate the safety and efficacy of this medication in reducing the level
of secondary hyperparathyroidism in pediatric patients with chronic kidney
diseases at stage 3 and 4. The drug is expected to complete its study in
December 2017, and be commercially available in market. However, side effects
usually associated with secondary hyperparathyroidism treatment such as muscle
spasm, diarrhea, and vomiting may cause hindrance to growth of the market.
Secondary Hyperparathyroidism
Treatment Market: Competitive Analysis
Key players operating in the
global secondary hyperparathyroidism treatment market include AbbVie, Inc.,
Shire, Inc., OPKO Health, Amgen, Inc., Sanofi SA, F. Hoffmann-La Roche AG,
Kyowa Hakko Kirin Co. Ltd., KAI Pharmaceuticals, Astellas Pharma, Inc.,
Deltanoid Pharmaceuticals, and Leo Pharma. Major players are focusing on
innovation and new product development, to maintain their position in the
market and enhance their share. For instance, in June 2016, OPKO Health
introduced Rayaldee (calcifediol) for the treatment of SHPT in adults with
stage 3 or 4 of chronic kidney disease.
Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1570
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and
competitive analysis through various recommendations related to emerging market
trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment